ATRA vs. ALVR, CRTX, SGMO, SLDB, PSTX, AGEN, BDTX, CRBU, ADAP, and IPSC
Should you be buying Atara Biotherapeutics stock or one of its competitors? The main competitors of Atara Biotherapeutics include AlloVir (ALVR), Cortexyme (CRTX), Sangamo Therapeutics (SGMO), Solid Biosciences (SLDB), Poseida Therapeutics (PSTX), Agenus (AGEN), Black Diamond Therapeutics (BDTX), Caribou Biosciences (CRBU), Adaptimmune Therapeutics (ADAP), and Century Therapeutics (IPSC). These companies are all part of the "medical" sector.
Atara Biotherapeutics (NASDAQ:ATRA) and AlloVir (NASDAQ:ALVR) are both small-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their earnings, risk, institutional ownership, media sentiment, profitability, dividends, community ranking, analyst recommendations and valuation.
Atara Biotherapeutics received 402 more outperform votes than AlloVir when rated by MarketBeat users. Likewise, 67.56% of users gave Atara Biotherapeutics an outperform vote while only 57.45% of users gave AlloVir an outperform vote.
AlloVir has a net margin of 0.00% compared to Atara Biotherapeutics' net margin of -671.70%. AlloVir's return on equity of -98.50% beat Atara Biotherapeutics' return on equity.
AlloVir has lower revenue, but higher earnings than Atara Biotherapeutics. AlloVir is trading at a lower price-to-earnings ratio than Atara Biotherapeutics, indicating that it is currently the more affordable of the two stocks.
In the previous week, Atara Biotherapeutics had 13 more articles in the media than AlloVir. MarketBeat recorded 16 mentions for Atara Biotherapeutics and 3 mentions for AlloVir. Atara Biotherapeutics' average media sentiment score of 1.02 beat AlloVir's score of 0.92 indicating that Atara Biotherapeutics is being referred to more favorably in the media.
70.9% of Atara Biotherapeutics shares are held by institutional investors. Comparatively, 66.1% of AlloVir shares are held by institutional investors. 3.7% of Atara Biotherapeutics shares are held by insiders. Comparatively, 33.9% of AlloVir shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.
Atara Biotherapeutics has a beta of 0.7, meaning that its stock price is 30% less volatile than the S&P 500. Comparatively, AlloVir has a beta of 0.79, meaning that its stock price is 21% less volatile than the S&P 500.
Atara Biotherapeutics presently has a consensus target price of $28.00, suggesting a potential upside of 4,419.04%. AlloVir has a consensus target price of $18.50, suggesting a potential upside of 2,314.83%. Given Atara Biotherapeutics' stronger consensus rating and higher possible upside, equities analysts plainly believe Atara Biotherapeutics is more favorable than AlloVir.
Summary
Atara Biotherapeutics beats AlloVir on 9 of the 17 factors compared between the two stocks.
Get Atara Biotherapeutics News Delivered to You Automatically
Sign up to receive the latest news and ratings for ATRA and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding ATRA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Atara Biotherapeutics Competitors List
Related Companies and Tools
